Better Together: BioCryst, Idera Merge To Improve Rare Disease Position
New company will have pair of Phase III candidates, an immuno-oncology licensing opportunity, strong experience in hereditary angioedema and roughly $243m in cash to position itself as a rare disease stronghold.
You may also be interested in...
Biocryst’s oral kallikrein inhibitor BCX7353 – already in Phase III for prophylaxis of hereditary angioedema – shows efficacy in a range of endpoints in a Phase II exploratory trial.
AZ’s MedImmune to use 4D’s AAV vector technology to deliver therapies for chronic lung disease, while Roivant spinout Dermavant licenses Phase III-ready autoimmune candidate tapinarof from GSK.
Potential upheavals in the hemophilia market bring uncertainty for Shire and Bayer, with executives likely to be quizzed on how they can retain market share during upcoming Q4 results calls. Scrip’s final earnings preview highlights the key challenges for large companies reporting at the tail-end of the earnings season.